Table I.
Characteristics of DLBCL patients, stratified by time from diagnosis to start of chemotherapy.
| All patients | Time from diagnosis to chemotherapy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| 0–7 days | 8–14 days | 15–30 days | >30 days | |||||||
| N | 104,465 | 15,728 | 18,903 | 35,744 | 34,090 | |||||
| Age, median (IQR); years | 66 | (55–75) | 65 | (53–75) | 65 | (54–75) | 66 | (55–75) | 66 | (56–76) |
| Sex, N (%) | ||||||||||
| Male | 56,395 | (54) | 8,489 | (54) | 10,506 | (56) | 19,307 | (54) | 18,093 | (53) |
| Female | 48,070 | (46) | 7,239 | (46) | 8,397 | (44) | 16,437 | (46) | 15,997 | (47) |
| Race / ethnicity, N (%) | ||||||||||
| White non-Hispanic | 86,350 | (83) | 12,865 | (82) | 15,554 | (82) | 30,245 | (85) | 27,686 | (81) |
| White Hispanic | 6,187 | (6) | 1,041 | (7) | 1,142 | (6) | 1,801 | (5) | 2,203 | (7) |
| Black | 6,857 | (7) | 988 | (6) | 1,271 | (7) | 2,068 | (6) | 2,530 | (7) |
| Asian/Other | 4,182 | (4) | 698 | (4) | 789 | (4) | 1,332 | (4) | 1,363 | (4) |
| Unrecorded | 889 | (1) | 136 | (1) | 147 | (1) | 298 | (1) | 308 | (1) |
| Comorbidity index, N (%) | ||||||||||
| 0 | 79,546 | (76) | 11,352 | (72) | 13,953 | (74) | 27,757 | (78) | 26,484 | (78) |
| 1 | 18,388 | (18) | 3,108 | (20) | 3,518 | (19) | 6,013 | (17) | 5,749 | (17) |
| 2 | 4,686 | (5) | 860 | (6) | 1,021 | (5) | 1,421 | (4) | 1,384 | (4) |
| ≥3 | 1,845 | (2) | 408 | (3) | 411 | (2) | 553 | (2) | 473 | (1) |
| Ann Arbor stage, N (%) | ||||||||||
| 1 | 25,204 | (24) | 2,596 | (17) | 3,558 | (19) | 8,703 | (24) | 10,347 | (30) |
| 2 | 21,653 | (21) | 2,902 | (19) | 3,703 | (20) | 7,567 | (21) | 7,481 | (22) |
| 3 | 20,161 | (19) | 3,029 | (19) | 3,822 | (20) | 7,282 | (20) | 6,028 | (18) |
| 4 | 35,908 | (34) | 6,935 | (44) | 7,530 | (40) | 11,703 | (33) | 9,740 | (29) |
| Unrecorded | 1,539 | (2) | 266 | (2) | 290 | (2) | 489 | (1) | 494 | (1) |
| B symptoms, N (%) | ||||||||||
| Absent | 63,843 | (61) | 8,018 | (51) | 10,433 | (55) | 22,427 | (63) | 22,965 | (67) |
| Present | 29,963 | (29) | 6,202 | (39) | 6,576 | (35) | 9,748 | (27) | 7,437 | (22) |
| Unrecorded | 10,659 | (10) | 1,508 | (10) | 1,894 | (10) | 3,569 | (10) | 3,688 | (11) |
| Primary site, N (%) a | ||||||||||
| Nodal | 71,242 | (68) | 12,028 | (77) | 13,763 | (73) | 24,399 | (68) | 21,052 | (62) |
| Extranodal, high risk | 15,846 | (15) | 2,337 | (15) | 2,924 | (16) | 5,157 | (14) | 5,428 | (16) |
| Extranodal, other | 17,377 | (17) | 1,363 | (9) | 2,216 | (12) | 6,188 | (17) | 7,610 | (22) |
| Radiation first, N (%) | ||||||||||
| No | 102,383 | (98) | 15,534 | (99) | 18,663 | (99) | 35,231 | (99) | 32,955 | (97) |
| Yes | 2,082 | (2) | 194 | (1) | 240 | (1) | 513 | (1) | 1,135 | (3) |
| IPI, N (%) b | ||||||||||
| Low | 5,587 | (31) | 485 | (19) | 740 | (22) | 2,168 | (33) | 2,194 | (39) |
| Low-Intermediate | 4,663 | (26) | 557 | (22) | 808 | (25) | 1,735 | (26) | 1,563 | (27) |
| High-Intermediate | 4,047 | (22) | 636 | (25) | 853 | (26) | 1,466 | (22) | 1,092 | (19) |
| High | 3,973 | (22) | 912 | (35) | 902 | (27) | 1,305 | (20) | 854 | (15) |
a
High-risk sites included central nervous system, lung, liver, pancreas, gastrointestinal tract, and bone marrow.(Castillo et al, 2014; Olszewski et al, 2015; Zhou et al, 2014)
b
Missing values omitted.
IPI: International Prognostic Index; IQR: interquartile range